Effects of chronic administration and withdrawal of antidepressant agents on circadian activity rhythms in rats by Wollnik, Franziska
Plumnarology BiocMmistry and &havlor, Vol. 43, pp. S49-S61, 1992 
Printed m the U.S.A. All rights reserved. 
0091-30S7/ 92 $5.00 + .00 
Copyright o 1992 Pergamon Press Ltd . 
Effects of Chronic Administration and 
Withdrawal of Antidepressant Agents on 
Circadian Activity Rhythms in Rats 
FRANZISK.A WOLLNIK 
Department of Biology, University of Konstanz, P.O. Box 5560, D-7750 Konstanz, Germany 
Received 10 December 1991 
WOLLNIK, F. E;ffects of chronic administration and Withdrawal of antidepressant agents on circadian activity rhythms in 
rats. PHARMACOL BIOCHEM BEHAV 43{2) S49-S61, 1992.-Experimental and clinical studies indicate that clinical 
depression may be associated with disturbances of circadian rhythms. To explore the interaction between circadian rhythmic-
ity, behavioral state, and monoaminergic systems, the present study investigated the effects of chronic administration and 
withdrawal of the following antidepressant agents on circadian wheel-running rhythms of laboratory rats: a) moclobemide, a 
reversible and selective monoamine oxidase (MAO) type A inhibitor; b) Ro 19-6327, a selective MAO type B inhibitor; c) 
desipramine, a preferential norepinephrine reuptalce inhibitor; d) clomipramine and e) fluoxetine, both serotonin reuptake 
inhibitors; and f) levoprotillne, an atypical antidepressant whose biochemical mechanism is still unknown. Wheel-running 
activity rhythms were studied in three inbred strains of laboratory rats (ACI, BH, LEW) under constant darkness (DD). Two 
of these inbred strains (BH and LEW) show proround abnormalities in their circadian activity rhythms, namely, a reduced 
overall level of activity and bimodal or multimodal activity patterns. Chronic treatment with moclobemide and desipramine 
consistently increased the overall level, as well as the circadian amplitude, of the activity rhythm. Furthermore, the abnormal 
activity pattern of the LEW strain was changed into a unimodal activity pattern like that of other laboratory rats. The 
free-running period r was slightly shortened by moclobemide and dramatically shonened by desipramine. Effects of moclobe-
mide and desipramine treatment on overall activity level and duration were reversed shortly after termination of treatment, 
whereas long aftereffects were observed for the free-running period. All other substances tested had no systematic effects on 
the activity rhythms of any of the strains. The fact that moclobemide and desipramine altered the period, amplitude, and 
pattern of circadian activity rhythms is consistent with the hypothesis that monoaminergic transmitters play a significant role 
in the neuronal control of behavioral state and circadian rhythmicity. Although the present study found that some antidepres-
sives affect parameters of circadian rhythmicity, it could not demonstrate a common effect of all classes of antidepressives. 
Circadian rhythms Genetic differences Inbred strains Antidepressives Moclobemide Ro 19-6327 
Desipramine Clomipramine Fluoxetine Levoprotiline 
IT has often been suggested that there is an association be-
tween the pathophysiology of affective disorders and disturb-
ances of circadian rhythms. For example, studies in humans 
have shown that affective disorders are associated with abnor-
malities in the period, phase, and/or amplitude of physiologi-
cal, behavioral, and endocrine rhythms, resulting in quite a 
number of different hypotheses on the chronobiology of de-
pression (16,18,20,39,41). Special attention has been paid to 
the observation that many circadian rhythms, including the 
circadian rhythm of rapid eye movement (REM) sleep and 
deep body temperature, are phase advanced in depressed pa-
tients compared to controls (12,27 ,42,43). 
According to the current knowledge about how circadian 
rhythms are generated and entrained (28), an abnormally ad-
vanced phase position of circadian rhythms could result from: 
a) an abnormally short period r of the underlying circadian 
pacemaker; b) an abnormal phase coupling between the intrin-
sic pacemaker and entraining signals such as the light-dark 
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cycle; and c) an abnormal phase coupling between the circa-
dian pacemaker and overt behavioral and physiological 
rhythms. 
In this context, it is of special significance that various 
antidepressant drugs can slow and delay circadian rhythms in 
animals [for reviews, see (8,43)]. Lithium, the first and most 
extensively studied psychoactive drug, lengthens the free-
running rhythm and delays the phase position in a variety of 
species, including marine algae, higher plants, insects, mam-
mals, and humans [for summaries, see (8,43,44)). Other anti-
depressant drugs that lengthen or phase delay circadian 
rhythms in mammals are clorgyline (7 ,25,37 ,45), a mono-
amine oxidase (MAO) type A inhibitor, pargyline (30,42), a 
mixed MAO type A and B inhibitor, and imipramine 
(13,25,43), a tricyclic monoamine reuptake inhibitor. How-
ever, the period-lengthening effect of imipramine seems less 
robust than that of clorgyline (2,8,36,45). In general, results 
of these and other studies have been interpreted to the effect 
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TABLE 1 
EFFECf OF CHRONIC DRUG TREATMENT (DAYS 15-28) ON BODY WEIGHT AND FOOD CONSUMPTION 
OF THE THREE INBRED STRAINS. ACI, BH, AND LEW 
Body weaght (g) 
Moclobemade Ro 19-6327 Desapramine Clomapramtne Fluoxetme Levoproubne 
Ammals Mean ± SE n Mean :t SE n Mean± SE n Mean± SE n Mean± SE n Mean± SE n 
ACl 
Day 152 ± 4.2 6 201 ± 4.7 5 190 • 2.8 ~ 6 214 ± 3.6 5 185 ± 14.9 6 184 ± 8.6 6 
Day 15 171 ± 3.4] 6 234 ± 6.3 j 5 199 ± 9.3 6 231 ± 2.9 J 5 194 ± 13.8] 5 207 ± 4.3 
J ! Day29 179 ± 4.6 6 228 ± 7.2 5 192 ± 5.6 6 230 ± 6.2 5 201 ± 5.0 5 220 ± 5.0 Day42 215 ± 3.7 6 230 ± 11.8 5 195 ± 5.8 6 240 ± 8.8 5 235 ± 5.8 5 214 ± 6.2 
BH 
Day I 176 ± 2.3 6 240 ± 5.5 6 131 ± 6.3 6 195 ± 10.8 5 229 ± 9.0 6 262 ± 13.7 6 
Day 15 254 ± 6.2] 6 256 ± 5.9 J 6 213 ± 11.3] 6 215 ± 18.3] 5 279 ± 16.7 j 6 316 ± 6.5 j 6 
Day29 263 ± 7.8 6 263 ± 14.7 6 226 ± 8.3 6 222 ± 6.5 5 282 ± 8.1 6 331 ± 8.6 5 
Day42 295 ± 10.8 6 296 ± 12.8 6 250 ± 7.9 6 257 ± 8.5 5 293 ± 6.4 6 345 ± 8.4 5 
LEW 
Day I 205 ± 7.4 6 250 ± 5.1 6 224 ± 14.5 6 277 ± 6.7 6 232 ± 9.2 6 276 ± 2.5 5 
Day 15 250 ± 7.2] 6 260 ± 10.2 ] 6 293 ± 19.5] 6 308 ± 16.8] 6 247 ± 1l.Oj 6 296 ± 10.3 j 5 
Day29 244 ± 5.5 6 259 ± 10.8 6 292 ± 13.6 6 304 ± 13.5 6 246 ± 9.2 6 304 ± 10.5 5 
Day42 277 ± 6.7 6 277 ± 9.3 6 326 ± 14.6 6 331 ± 11.3 6 255 ± 11.7 6 317 ± 8.2 5 
Fs.tau» (2, 60) = 147.6* (2, 56) 130.6* (2, 60) 1.85* (2. 52) 79.4* (2, 57) 175.6* (2, 54) 205.4* 
Foays (3, 60) = 82.9* (3, 56) 5.5* (3, 60) 6.8• (3, 52) 10.7* (3, 57) 9.1* (3, 54) 16.9* 
FJnteraetiOn$ (6, 60) = 6.9* (6, 56) 3.1* (6, 60) 3.4* (6, 52) 3.0* (6, 57) 3.5* (6, 54) 3.8• 
Food consumpuon (g/lOOg BW) 
Moclobemide Ro 19-6327 Desapramme Clomaprarrune Fluoxeune Levoprotahne 
Ammals Mean ± SE n Mean± SE n Mean ± SE n Mean± SE n Mean ± SE n Mean± SE n 
ACI 
Day 1-7 75.2 ± 3.9 6 52.4 ± 4.5 5 80.3 ± 1.8 6 64.0 ± 2.5 5 69.5 ± 5.4 6 72.3 ± 7.0 6 
Day 8-14 71.0 ± 3.4 6 59.7 ± 2.2 5 67.2 ± 4.2 6 65.1 ± 2.0 5 64.1 ± 2.5 6 64.9 ± 3.8 6 
Day 15-21 65.2 ± 4.3 6 63.9 ± 2.9 5 43.9 ± 4.3 6 38.6 ± 3.6 5 59.0 ± 4.7 5 68.0 ± 4.6 6 
Day 22-28 63.7 ± 1.1 6 62.3 ± 2.1 5 55.3 ± 1.9 6 49.0 ± 2.1 5 46.6 ± 2.5 5 62.5 ± 3.9 6 
Day 29-35 70.5 ± 1.9 6 66.4 ± 5.5 5 66.0 ± 2.7 6 58.0 ± 2.5 5 71.2 ± 2.2 5 62.5 ± 4.1 5 
Day 36-42 62.9 ± 2.0 6 52.3 ± 3.1 5 40.6 ± 4.4 6 42.5 ± 2.3 5 57.9 ± 2.3 5 56.3 ± 6.6 5 
BH 
Day 1- 7 72.7 ± 4.3 6 32.6 ± 6.8 6 68.7 ± 2.6 6 46.5 ± 5.1 5 64.6 ± 2.2 6 61.6 ± 4.9 6 
Day 8-14 64.1 ± 1.3 6 39.6 ± 5.2 6 68.5 ± 2.1 6 65.4 ± 4.2 5 51.0 ± 1.7 6 48.9 ± 1.0 6 
Day 15-21 60.8 ± 1.1 6 58.0 ± 5.7 6 50.5 ± 1.6 6 54.2 ± 5.6 5 53.1 ± 5.6 6 53.8 ± 3.3 6 
Day 22-28 54.2 ± 1.3 6 45.2 ± 3.5 6 56.1 ± 1.4 6 46.9 ± 1.0 5 37.6 ± 3.6 6 44.8 ± 1.0 6 
Day29-35 67.2 ± 4.9 6 48.7 ± 5.2 6 59.1 ± 3.2 6 53.7 ± 5.8 5 41.5 ± 7.7 6 46.9 ± 3.9 5 
Day 36-42 53.8 ± 2.5 6 46.9 ± 6.2 6 59.9 ± 3.0 6 47.8 ± 2.3 5 48.0 ± 4.8 6 47.8 ± 2.2 5 
LEW 
Day 1-7 68.0 ± 1.2 6 38.6 ± 4.0 6 69.5 ± 7.9 6 55.3 ± 3.6 6 44.0 ± 2.3 6 48.3 ± 3.4 5 
Day 8-14 65.4 ± 1.3 6 42.8 ± 2.5 6 57.6 ± 8.4 6 52.8 ± 5.7 6 38.7 ± 2.6 6 48.0 ± 3.3 5 
Day 15-21 53.4 ± 2.0 6 45.9 ± 2.6 6 41.0 ± 6.0 6 32.6 ± 2.6 6 38.9 ± 1.4 6 55.8 ± 5.4 5 
Day 22-28 56.8 ± 1.6 6 36.5 ± 1.6 6 49.4 ± 7.2 6 41.9 ± 2.2 6 31.0 ± 1.0 6 43.7 ± 4.7 5 
Day 29-35 58.7 ± 1.9 6 46.6 ± 1.9 6 55.4 ± 5.5 6 48.0 ± 2.6 6 46.0 ± 2.1 6 54.1 ± 3.7 5 
Day 36-42 58.4 ± 2.4 6 40.5 ± 4.0 6 54.4 ± 7.7 6 40.2 ± 1.7 6 35.4 ± 2.5 6 40.8 ± 4.1 5 
Fs., .... (2, 90) = 14.7* (2, 84) 36.6* (2, 90) 4.9* (2, 78) 9.2* (2, 88) 57 .8* (2, 80) 25.3* 
Frn.ys (5, 90) = 34.8* (5, 84) 3.8t (5, 90) 26.5* (5, 78) 14.0* (5, 88) II. I* (5, 80) 3.9* 
F lntcracuoM (10, 90) = 2.2t (10, 84) 2.2t (10, 90) 2.5* (10, 78) 3.1* (10, 88) 2.2t (10, 80) 2.9* 
*Differences between strains, pharmacological treatments, and strain-treatment interactions were assessed using standard procedures of 
ANOVA (two-way ANOVA for repeated measurements). Brackets indicate body weight values that were not significantly different from each 
other. 
*p :S 0.01. 
tp :s 0.05. 
ANTIDEPRESSANTS AND CIRCADIAN RHYTHMS 
TABLE2 
AVERAGE UPTAKE RATES OF ANTIDEPRESSANT 
AGENTS FOR ACI, BH AND LEW RATS 
Daily Drug Intake (mg/kg body weight) 
ACJ BH LEW 
Moclobemide 28 27 25 
Ro 19-6327 3.6 3 2.4 
Desipramine 32 34 29 
Oomipramine 23 27 23 
Fluoxetine 11 10 8 
Levoprotiline 43 32 32 
that these drugs slow the mammalian circadian pacemaker. 
However, some studies reported additional effects such as dis-
sociation (45) and splitting (19) of circadian rhythms, while 
others found no effect of antidepressant drugs on the circa-
dian period at all (2,29,36). 
It should be noted that almost all these investigations ex-
amined the effects of psychoactive drugs on animals such as 
golden hamsters or laboratory rats that have "normal" circa-
dian rhythms rather than "abnormal" rhythms that might be 
more representative of clinical depression. To my knowledge, 
there is only one study that demonstrates how chronic antide-
pressant administration can reestablish a normal phase posi-
tion in animals with a phase-advanced activity rhythm caused 
by complete social isolation (13). 
To account for this deficiency, this study used two com-
monly available inbred strains, BH and LEW, of laboratory 
rats with genetically fixed differences in circadian rhythm pa-
rameters (46-48). These strains have rather unusual activity 
patterns that may be caused by multiple circadian oscillators 
coupled to each other with a phase relationship of 4-6 h 
(34,46-48). The goal of the study was to investigate the effects 
of various antidepressant drugs on the circadian wheel-
running rhythms of the two strains compared to strain ACI, 
which shows an activity pattern found in most laboratory rats. 
In a chronic drug administration protocol, the major types of 
drugs used to treat affective disorders were tested: a) moclobe· 
mide, a reversible and highly selective type A MAO inhibitor 
(4,5); b) Ro 19-6327, a selective type 8 MAO inhibitor (14); c) 
desipramine, a tricyclic preferential norepinephrine reuptake 
inhibitor (17,21); d) clomipramine, a tricyclic preferential se-
rotonin reuptake inhibitor (49); e) fluoxetine, a nontricyclic 
selective serotonin reuptake inhibitor (l I ,17 ,49); and f) levo-
protiline, the (- )-enantiomer of oxaprotiline with an un-
known biochemical mechanism (6,21). 
MBTHOD 
Animals and Housing 
Male rats of the inbred strains ACI/Ztm (agouti), BH/ 
Ztm (black hooded), and LEW /Ztm (albino), originally ob-
tained from the central animal laboratory at the Hanover 
Medical School (Germany), were bred and raised in our labo-
ratory under controlled environmental conditions (12 L: 12 D 
cycle, lights on at 0700 h, room temperature 22 ± 1 °C}. For 
each experiment six littermates of each strain, to-12 weeks 
old, were singly housed in cages (Makrolon [Becker, Castrop-
Ratixel, Germany] Type IV, 35 x 55 x 10 em) equipped with 
a running wheel (diameter 35 em, width 10 em). Groups of 
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four running wheel cages each were housed within ventilated, 
light-tight, stainless steel compartments. Wheel-running activ-
ity was monitored under constant dark conditions (DD) for 
6-8 weeks. Animals had free access to the running wheel; food 
and water were supplied ad lib. Animals were checked once 
per week at irregular times during their subjective night, that 
is, during their active phase, using an infrared light viewer 
(FJW Optical Systems, Inc., Palatine, IL). At these occasions, 
remaining food was weighed, food and water were replen-
ished, and cages were changed if necessary. 
Data Collection and Anolysis 
Three magnetic reed switches were mounted on each run-
ning wheel axle so that one complete wheel revolution resulted 
in three impulses. The number of impulses per 5-min interval 
was recorded continuously by a microcomputer (Apple II+). 
All subsequent calculations were based on these 5-min counts. 
Periods r of the free-running circadian rhythm were esti-
mated using the x2 periodogram (35). Harmonic spectral anal-
ysis (15,26) was used to verify the presence of characteristic 
frequencies in the data. Further details of the statistical mod-
els underlying these two approaches are described elsewhere 
(46,47). 
Additional parameters calculated from the activity record-
ings include: a) overall level of activity, defined as total num-
ber of counts over a 24-h period given in impulses/day; b) 
duration of wheel-running activity, defmed as total length of 
all 5-min intervals within 24 h containing more than 5 impulses 
given in min/day. In all experiments, differences between 
strains and pharmacological treatments were evaluated by 
two-way analyses of variance (ANOV As) for repeated mea-
surements, followed by Tukey's multiple /-test for individual 
mean comparisons. Pearson's r was used for expressing corre-
lations. 
Procedures 
Separate experiments were conducted for each of the six 
substances. In each experiment, five to six animals of each 
strain were recorded. After 14 days of free-running baseline 
conditions, the following antidepressant agents were adminis-
tered for 14 days: moclobemide, Ro 19-6327, desipramine, 
clomipramine (all supplied by F. Hoffman-La Roche Ltd., 
Basel, Switzerland), fluoxetine (supplied by Lilly, Indianapo-
lis, IN), and levoprotiline (supplied by CIBA-GEIGY Ltd., 
Basel, Switzerland). After 14 days, drug treatment was termi-
nated and the recording was continued for 2 more weeks with 
normal food. The antidepressants were administered ad lib in 
food mixtures prepared by KLIW A. The mixtures were identi-
cal to the standard powdered diet used during baseline and 
withdrawal conditions except they contained the following 
concentrations of antidepressants per kg food: moclobemide, 
300 mg/kg; Ro 19-6327, 40 mg!kg; desipramine, 375 mg/kg; 
clomipramine, 450 mg/kg; fluoxetine, 152 mg/kg; levoproti-
line, 450 mg/kg. Assuming a daily food intake of approxi-
mately 20 g for a rat of 300 g body weight, these food mixtures 
produced an average daily drug intake per kg body weight of 
20 mg moclobemide, 2.5 mg Ro 19-6327,25 mg desipramine, 
30 mg clomipramine, 10 mg fluoxetine, and 30 mg levoproti-
line. These doses bad been found to be most effective for 
chronical treatment of rats (personal communications with F. 
Hoffman-La Roche Ltd., Lilly, and CIBA-GEIGY Ltd.). The 
powdered food was provided in a glass jar braced against the 
cage with a wire spring. Food intake was measured every week 
and body weight every 2 weeks during the regular checks of 
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FIG. I. Characteristic recordmgs of wheel-running activity from ACI, BH, and LEW rats. Following 14 days of baseline condluons, 
ammals wre chrorucally treated with moclobemide (a), Ro 19-6327/ 001 (b), desipramine (c), clonupramine (d), fluoxeune (e), or 
levoprotihne (f). Numbers on the venical axes denote days of experiment; numbers on the horizontal axes denote daytime hours. 
Activity records are shown as doule plots to facilitate visualization of free-running rhythms. Each 48-h period consists of 144 bins, 
where the height of each bin represents the number of impulses during a 20-min interval (20-200 impulses/bm). 
animals. Statistical parameters of the wheel-running rhythms 
were computed for each of the following three conditions: 
baseline (days 1- 14), drug treatment (days 15-28), and drug 
withdrawal (days 29-42). 
RESULTS 
Body Weight and Food Consumption 
Measurements of body weight and food consumption are 
summarized in Table 1. Repeated-measures ANOV A indi-
cated significant differences between body weights of the three 
strains, with animals of the ACI strain being generally lighter 
than animals of the BH and LEW strains. In all six experi-
ments, drug treatment (days 14- 28) caused a temporary halt 
in the otherwise continuous increase in body weight, and 
sometimes even a decrease, for example, in the ACI strain 
under Ro 19-6327, desipramine, and clomipramine treatment. 
However, these effects were minor and did not affect the 
health or well-being of animals. 
Due to the strain differences in body weight, measurements 
of food intake were expressed with respect to body weight. As 
could be expected from the interruption in body weight gain, 
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FIG. 1. Continued. 
food intake was reduced mostly during drug treatment. The 
only substance to slightly increase food intake in all three 
strains was Ro 19-6327. Food intake data were used to esti-
mate the average daily uptake rates of antidepressant agents 
summarized in Table 2. Average uptake rates were well within 
the expected range for moclobemide (20 mglkg), Ro 19-6327 
(2.5 mg!kg), desipramine (25 mg/kg), fluoxetine (10 mglkg), 
and levoprotiline (30 mglkg). Only in the case of clomipram-
ine was food intake dramatically reduced, resulting in an aver-
age drug intake of less than the expected rate of 30 mg/ kg. 
Strain Differences in Wheel-Running Activity 
Characteristic activity recordings from the various antide-
pressant treatments are shown in Figs. la- lf, where each re-
cording represents one animal of a particular strain. During 
baseline conditions, all animals displayed clear free-running 
rhythms. As expected, the circadian pattern of wheel-running 
activity was highly strain dependent. Strain ACI exhibited the 
strongest activity rhythm characterized by a high activity level 
and well-defined activity onsets and offsets. Strain BH showed 
a weaker activity rhythm with blurred onsets and offsets and 
expanded times of activity. The activity pattern of the LEW 
strain was characterized by two, sometimes three, short activ-
ity bouts about 4-5 h apart. When analyzed with the harmonic 
spectral analysis and the periodogram, characteristic frequen-
cies were detected for each of the three strains. Periodogram 
analyses of the activity pattern of strain ACI revealed an aver-
age circadian period of 1' = 24 h 22 min during baseline condi-
tions, whereas the free-running periods 1' = 24 h 1 5 min of 
strain BH and 1' = 24 h S min of strain LEW were generally 
shorter. BH and LEW rats were characterized by additional 
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TABLE 3 
EFFECTS OF CHRONIC ANTIDEPRESSANT DRUG TREATMENT ON OVERALL ACTIVITY LEVEL (IMPULSES/DAY) AND 
DURATION OF ACTIVITY (mm/DAY) lN ACI , BH, AND LEW RATS 
Overall Level of Acnvuy (Impulses/day) 
Moclobemrde Ro 19·6327 Desipramme Clomrpramine Pluoxetrne Levoproulinc 
Arumals Mean :t: SE n Mean± SE n Mean± SE n Mean± SE n Mean± SE n Mean :t: SE n 
ACI 
B 1,527 ± 417 6 3,125 ± 299 5 1,603 ± 173 6 1,678 ± 436 5 2.222 :!: 442 6 2,103 ± 272 6 
T 2,078 ± 352*t 6 2,880 ± 199 5 2,257 ± 540*t 6 1,468 ± 444 5 1,727 ± 223 5 2,675 ± 377*t 6 
w 1,191 ± 228 6 2,584 ± 366 5 1,434 ± 270 6 1,258 :t 245 5 1,450 ± 159 5 1,152 ± 214* 5 
BH 
B 1,011 ± 113 6 542 ± 77 6 480 ± 43 6 1,554 ± 243 5 831 ± 147 6 754 ± 134 6 
T 1,862 ± 297 6 547 ± 80 6 1,747 ± 176* 6 1,356 ± 232 5 1,036 ± 189 6 1,051 ± 164 6 
w 1,657 ± 302 6 505 ± 56 6 I ,591 ± 355* 6 1,154 ± 342 5 1,066 ± 89 6 776 ± 81 5 
LEW 
B 910 ± 152 6 582 ± 104 6 601 ± 164 6 554 ± 63 6 449 ::t 50 6 555 ± 56 5 
T I ,479 ± 234*t 6 580 ± 90 6 1,339 ± 329*t 6 598 ± 180 6 388 ::t 53 6 747 ± 76 5 
w 675 ± 128 6 570 ± 95 6 361 ± 106 6 435 ± 69 6 355 ± 49 6 690 ± 83 5 
E 
B 1,146 ± !58 18 1,548 ± 377 17 853 ± 142 18 1,262 ± 205 16 1,167 ± 236 18 1,266 ± 243 17 
T 1,806 ± 172*t 18 1,455 ± 335 17 1,753 ± 213*t 18 1,140 ± 194 16 1,011 ± 161 17 1,535 ± 254*t 17 
w 1,174 ± 158 18 1,220 ± 313 17 1,158 ± 206 18 949 ± 164 16 919 ± 132 17 872 ± 90* 15 
FstraJ.rl$ (2, 45) = 4.U (2, 42) 147 .4§ (2, 45) 9.2§ (2, 39) 9.9§ (2, 43) 38.6§ (2, 40) 34.0§ 
FTreaunent (2, 45) = 5.9§ (2, 42) 2.2 ns (2, 45) 8.6§ (2, 39) 0.9 ns (2, 43) 1.2 ns (2, 40) 8.5§ 
Ft ntcra«•ons (4, 45) = 3.U (4, 45) 0.8 ns (4, 45) 3.6t (4, 39) 0.1 ns (4, 43) 1.5 ns (4, 40) 3.9§ 
Duratron of Acuvrty (mm/day) 
Moclobemrde Ro 19·6327 Desrpramme Clomrpramme F1uoxetme Levoprotrhne 
Ammals Mean± SE n Mean ± SE n Mean± SE n Mean ± SE n Mean± SE n Mean± SE n 
ACI 
B 360 ± 33 6 532 ± 29 5 335 ± 65 6 366 ± 53 5 443 ± 43 6 440 ± 24 6 
T 418 ± 32*t 6 503 ± 20 5 470 ± 27*t 6 325 ± 48 5 391 ± 22 5 469 ± 42 6 
w 361 ± 34 6 493 ± 27 5 300 ± 38 6 304 ± 40 5 362 ± 22 5 343 ± 21* 1 5 
BH 
B 376 ± 26 6 271 ± 37 6 234 ± 22 6 449 ± 39 5 326 ± 36 6 300 ± 24 6 
T 482 ± 46* 6 291 ± 30 6 499 ± 34*t 6 438 ± 56 5 343 ± 44 6 353 ± 26 6 
w 450 ± 48* 6 262 ± 22 6 371 ± 60 6 362 ± 59 5 350 ± 31 6 257 ± 25 5 
LEW 
B 253 ± 18 6 216 ± 16 6 205 ± 27 6 180 ± 10 6 148 ± 8 6 205 ± 12 5 
T 330 ± 28*t 6 203 ± 13 6 312 ± 52*t 6 182 ± 32 6 141 ± 10 6 231 ± 10 5 
w 207 ± 24 6 187 ± 13 6 153 ± 23 6 146 ± 13 6 128 ± 10 6 194 ± 10 5 
E 
B 330 ± 20 18 354 ± 44 17 253 ± 19 18 332 ± 36 16 306 ± 34 18 334 ± 31 17 
T 410 ± 25*t 18 345 ± 39 17 424 ± 34*t 18 315 ± 37 16 286 ± 32 17 353 ± 31 17 
w 339 ± 32 18 314 ± 41 17 281 ± 34 18 271 ± 33 16 270 ± 31 17 265 ± 18*1 15 
Fsua~ns (2, 45) = 20.9§ (2, 42) 135.2§ (2, 45) 11 .5§ (2, 39) 26.2§ (2, 43) 68.3§ (2, 40) 51.9§ 
FT,tatment (2, 45) = 5.2§ (2, 42) 2.2 ns (2, 45) 14. 7§ (2, 39) 1.6 ns (2, 43) 1.1 ns (2, 40) 10.9§ 
FJnte-ractaons (4, 45) = 3.9§ (4, 42) 0.2 ns (4, 45) 4.9§ (4, 39) 0.2 ns (4, 43) 0.6 ns (4, 40) 3.4t 
*Differences between strains, pharmacological treatments, and strain-treatment interactions were assessed using standard procedures of ANOV A 
(two-way ANOV A for repeated measurements). Compansons of baseline (B), tratment (T), and withdrawal (W) conditions were performed usmg 
Tukey's multiple r-test. ns, not significant. 
*Significant difference (p s 0.05) from baseline condition. 
tSignificant difference from withdrawal. 
tp s 0.05. 
§p s 0.01 
1Significant difference from treatment. 
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FIG. 2. Effects of moclobemide treatment. Left column: circadian waveform of wheel-running activity of ACl (a, n = 6}, BH (c, 
n = 6), and LEW (e, n = 6) rats during baseline conditions (upper panel), treatment (middle panel), and withdrawal (lower 
panel). Thirty-minute mean values are plotted as a function of the free-running period with standard deviation between animals 
shown as vertical lines. Right column: average power spectra for strains ACl (b), BH (d), and LEW (f) calculated from harmonic 
spectral analyses of individual animals. The 950Jo confidence limits of spectral estimates are plotted as vertical lines. Asterisks 
mark estimates that are significantly different from corresponding values during baseline conditions (•p < 0.05; .. P < 0.01). 
Amplitudes of spectral estimates: ACl- 24-hbuctmc = 6,291 ± 296, 24-hmodobanlcl< = 7,168 ± 299, 24-h ..... bclrawaJ = 4,887 ± 882; 
BH-24-~ = 3,127 ± 339, 24-~ = 3,44a ± 482, 24-h-wa~ = 2,376 ± 488; LEW-24-~ .. = 5,880 ± 293, 
24-h- = 7,436 ± 177, 24-h...,tbdl&wal = 6,518 ± 199; 4.8-hbudiDC = 1,820 ± 191, 4.8-hiiiOC_,ck = 882 ± 214, 4.8-h...,thclrawol 
= 2,365 ± 189;4-hbuclul< = 2,134 ± 183,4-hmoclobcmlck = 6SO ± 162,4-h,..llhd,.wal = 1,871 ± 288. 
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TABLE4 
EFFECfS OF CHRONIC ANTIDEPRESSANT DRUG TREATMENT ON THE FREE-RUNNING PERIOD T OF 
CIRCADIAN WHEEL-RUNNING ACfiVITY RHYTHMS rN ACl , BH, AND LEW RATS 
Free-Runnmg Penod (h) 
Moclobem•de Ro 19-6327 Des1pramme Clonupramine Fluoxetme Levoprotiline 
Animals Mean± SE n Mean± SE n Mean± SE n Mean ± SE n Mean± SE n Mean ± SE n 
ACI 
B 24.47 ± 0.05 6 24.42 ± 0.03 5 24.38 ± O.o3 6 24.43 ± 0.12 5 24.25 ± 0.04 6 24.29 ± 0.02 6 
T 24.35 ± o.o5• 6 24.24 ± 0.08 5 24.29 ± 0.02 6 24.28 ± 0.02 5 24.22 ± O.Q7 5 24.25 ± 0.05 6 
w 24.35 ± 0.03• 6 24.38 ± 0.04 s 24.18 ± 0.02° 6 24.45 ± 0.03 5 24.23± 0.08 s 24.45 ± 0.05 5 
BH 
B 24.12 ± 0.05 6 24.38 ± 0.09 6 24.22 ± 0.08 6 24.18 ± O.o3 5 24.32 ± O.o3 6 24.32 ± 0.04 6 
T 23.95 ± 0.03*t 6 24.33 ± O.Q7 6 23.87 ± 0.07° 6 24.22 ± 0.08 5 24.28 ± 0.03 6 24.31 ± 0.03 6 
w 23.83 ± 0.04°§ 6 24.33 ± 0.09 6 23.81 ± 0.09• 6 24.23 ± O.o? 5 24.31 ± 0.05 6 24.23 ± 0.06 5 
LEW 
B 23.78 ± 0.02 6 24.21 ± 0.05 6 24.02 ± 0.06 6 23.73 ± 0.1 6 24.34 ± 0.04 6 24.22 ± 0.04 5 
T 23.65 ± 0.03* 6 24.27 ± 0.04 6 23.69 ± 0.09• 6 23.95 ± 0.07 6 24.51 ± 0.05 6 24.22 ± 0.02 s 
w 23.68 ± o.o5• 6 24.29 ± 0.21 6 23.71 ± 0.14° 6 23.75 ± 0.17 6 24.57± 0.04 6 24.29 ± 0.04 s 
I: 
B 24.12 ± 0.07 18 24.35 ± 0.04 17 24.19 ± 0.05 18 24.16 ± 0.09 16 24.31 ± 0.02 18 24.28 ± 0.02 17 
T 23.98 ± 0.07* 18 24.27 ± 0.04 17 23.94 ± 0.07° 18 24.15 ± 0.05 16 24.34 ± 0.04 17 24.26 ± 0.02 17 
w 23.95 ± 0.07* 18 24.34 ± 0.04 17 23.89 ± 0.07° 18 24.14 ± 0.09 16 24.37 ± 0.05 17 24.32 ± 0.03 IS 
Fsua'ns (2, 45) = 20.8§ (2, 42) 1.6 ns (2, 45) 26.8§ (2, 39) 31. 9§ (2, 43) 19.7§ (2, 40) 2.9 ns 
FTrca1mat (2, 45) = 14.8§ (2, 42) 1.0 ns (2, 45) 13.1§ (2, 39) 0.1 ns (2, 43) 1.3 ns (2, 40) 1.9 ns 
Flnter~•ons (4, 45) = 2.7t (4, 42) 1.0 ns (4, 45) 3.3t (4, 39) 1.4 ns (4, 43) 2.3 ns (4, 40) 1.3 ns 
For methods and notations, see Table 3. 
rhythmic components of approximately 12 and 6 h and 4.8 
and 4 h, respectively. 
Effects of Antidepressants on Circadian Rhythms 
Of the antidepressant agents tested, only two, moclobe-
mide and desipramine, clearly affected parameters of circa-
dian wheel running activity (Figs. la-lt). The effects of drug 
treatment on the overall level and duration of activity are 
summarized in Table 3. 
Chronic treatment with moclobemide induced significant 
changes in the overall level, F(2, 45) = 5.9, p < 0.01, and 
duration of activity, F(2, 45) = 5.2, p < 0.01, in all three 
strains. Tukey's multiple /-test revealed a significant increase 
in the overall level and duration of activity during moclobe-
mide treatment compared to both baseline and withdrawal 
conditions and no significant differences between baseline and 
withdrawal. Figures 2a-2f illustrate the average waveform of 
circadian activity and pooled power spectra of each strain 
during baseline condition, moclobemide treatment, and with-
drawal. In all three strains, moclobemide treatment resulted 
in an increase of the amplitude of the circadian waveform. In 
the power spectrum analysis, this is expressed by an increase 
of the 24-h peak. In addition, moclobemide treatment altered 
the pattern of activity in the LEW strain. As shown in Fig. 
2e, moclobemide treatment changed the characteristic multi-
modal activity pattern of the LEW strain during baseline con-
ditions into a unimodal activity pattern similar to that of the 
control strain ACL Trus effect disappeared after terminating 
the treatment. Power spectrum analysis confirmed these find-
ings (Fig. 2f). The amplitude of the 24-h peak was increased 
during moclobemide treatment, whereas the characteristic 
peaks at 4 and 4.8 h were reduced to nonsignificant levels. 
Results for free-running period are summarized in Table 4. 
Two-way ANOV A revealed significant strain differences, F(2, 
45) = 20.8, p < 0.01, as well as significant effects of treat-
ment, F(2, 45) = 14.8, p < 0.01. Multiple t-test comparisons 
revealed a small but significant shortening (8 min) of the free-
running period during moclobemide treatment. However, this 
effect was not reversed during withdrawal. 
Total drug intake over the 2 weeks of moclobemide treat-
ment was not significantly correlated with moclobemide-
induced alterations in any of the circadian parameters mea-
sured. Furthermore, when evaluating the data for possible 
relationships between baseline values and treatment-induced 
alterations no significant pairwise correlations could be de-
tected between baseline values and treatment effe.cts for either 
overall activity level, duration, or free-running period. 
Desipramine had even more dramatic effects on the circa-
dian wheel-running rhythm of all three strains than moclobe-
mide (Figs. lc and 3). Desipramine treatment caused a signifi-
cant increase in the overall level, F(2, 45) = 8.6, p < 0.01, 
and duration of activity, F(2, 45) = 14.7, p < 0.01 (Table 
3). Total drug intake over the 2 weeks of desipramine treat-
ment was positively correlated with drug-induced changes in 
overall level (r = 0.77, p < 0.01) and duration (r = 0.75, 
p < 0.01) of activity. No significant correlation could be de-
tected between baseline values and desipramine-induced ef-
fects for any of the circadian parameters tested. Similar to 
moclobemide, desipramine treatment affected the average pat-
tern of circadian activity in all three strains. In ACI and LEW 
strains, the amplitude of the 24-h peak was increased during 
desipramine treatment, although this increase did not prove 
significant (Figs. 3b and 3f). The effect of desipramine treat-
ment was most pronounced for the multimodal activity pat-
tern of the LEW strain. As shown in Fig. 3e, desipramine 
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FIG. 3. Effects of desipramine treatment. Circadian waveform of wheel-running activity and harmonic spectral analyses of AO 
(a,b n = 6), BH (c,d n = 6), and LEW (e,f n = 6) rats during baseline conditions (upper panel), treatment (middle panel), 
and withdrawal (lower panel). Amplitudes of spectral estimates: ACI-24-h- • 5,610 ± 544, 24-b.s..i_.,_ = 6,617 ± 461, 
24-b-,.wo~ = 6,100 ± 394; BH-24-ht-w,. = 4, 128 ± 234, 24-h.!,...,...... • 3,576 ± 210, 24-h-.. .... = 4,407 ± 339; 
LEW-24-h- = 4,863 ± 558, 24-~ = 5,431 ± 351, 24-h...lhdrawal • 5, 134 ± 568; 4.8-h._._ = 3,642 ± 635, 4.8-
h.!,..p,....,. = 490 ± 159, 4.8-hWltbdrowal = 3,140 ± 314; 4-bl>ueluM = 2,606 ± 285, 4-ba...pnuruec = 259 ± 68, 4-h-rowal = 3,007 
± 570; For further explanations, see Fig. 2. 
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treatment of LEW rats resulted in a unimodal activity pattern 
similar to that seen in ACI rats during baseline and withdrawal 
condition. Power spectrum analyses conf1rmed these results 
(Fig. 3f). The characteristic peaks at 4.8 and 4 h detected 
during baseline and withdrawal were completely absent during 
desipramine treatment. 
Furthermore, desipramine treatment clearly affected the 
free-running period of all three strains (Fig. lc and Table 4). 
ANOVA revealed a significant shortening of r during desipra-
mine treatment (ACI tu = - 5 min; BH AT = - 20 min; 
LEW Ar = - 13 min). Remarkably, this effect persisted dur-
ing the first 2 weeks of withdrawal. Because the experiment 
was terminated after 42 days, it is not known whether the 
shortening of r would have returned to baseline values after a 
longer period of drug withdrawal. 
All other substances tested, that is, Ro 19-6327, clomi-
pramine, fluoxetine, and levoprotiline, failed to induce sys-
tematic changes in the circadian wheel-running rhythm of all 
of the three strains (Figs. I b and ld- f). Repeated two-way 
ANOV A revealed significant changes only during levoproti-
line treatment, where a small increase in the overall level and 
duration of activity was found (Table 3). 
DISCUSSION 
This study investigated the effects of various clinically ef-
fective antidepressants on circadian activity rhythms in spe-
cific inbred strains of laboratory rats. The objective was to 
possibly identify effects common to all of them. Of the six 
substances tested, only two, moclobemide and desipramine, 
induced significant changes in parameters of wheel-running 
activity. Both agents increased the overall level, as well as the 
duration, of activity. Although these effects were observed in 
all three strains, they were most pronounced in the LEW 
strain, which had the lowest activity level and the shortest 
duration of activity during baseline conditions. Furthermore, 
both agents affected the activity pattern of LEW rats, chang-
ing the rather unusual multimodal pattern into the unimodal 
pattern normally seen in laboratory rats. Specifically, the 
characteristic periodic components of 4 and 4.8 h were absent 
during treatment. 
Moclobemide and desipramine also induced a shortening 
of the free-running period. From what is presently known, a 
shortening of the free-running period of the circadian pace-
maker causes an advance of the phase position of entrained 
rhythms (28). A recent investigation (3) of desipramine treat-
ment in rats (also administered via food; however, in a two-
fold concentration compared to the present study) indeed 
showed a phase advance ( + 70 min) of the temperature rhythm 
under LD entrainment, supporting our finding that desipra-
mine affects the period of the circadian pacemaker. Moreover, 
the study also failed to demonstrate an effect of clomipramine 
(again given in a twofold concentration) on the phase of tem-
perature rhythms, consistent with our finding that clomipram-
ine does not affect the free-running period. 
However, there are also a few incongruencies that need to 
be discussed. First, in the present study the period shortening 
during desipramine and moclobemide treatment was not re-
versed during withdrawal conditions. Whether or not these 
period changes were due to other effects, for example, aging 
of animals, could have been clarified by including a nontreat-
ment control group to monitor the extent of spontaneous 
changes in the period. However, because no such changes 
were observed for the other ineffective antidepressant agents, 
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which could thus be regarded as controls, the penod shorten-
ing appears to be a true effect of the drug treatment. 
Second , the rather convenient procedure of drug applica-
tion via food does not allow precise drug dosage because it 
includes the possibility of drug self-administration or food 
aversion due to the unfamiliar flavor or task of the food. 
Except in the case of Ro 19-6327, drug treatment resulted in a 
decline of food consumption and halt or decline of body weight, 
both of which returned to baseline levels after treatment termi-
nation. These are typical effects of flavor or task aversion. 
However, it seems unLikely that the changes during moclobe-
mide and desipramine treatment were only side effects of the 
reduced food intake and body weight because a similar reduc-
tion was seen for other agents that did not affect circadian 
rhythm parameters. Nevertheless, it would be desirable to verify 
that the effects of moclobemide and desipramine treatment 
seen in the present study can be reproduced under continuous 
drug administration using implanted osmotic pumps. 
ln the present study, Ro 19-6327, clomipramine, fluoxe-
tine, and levoprotiline failed to have an effect on circadian 
wheel-running rhythms. The negative result for Ro 19-6327 
could have been expected because of the positive effect of 
moclobemide. The enzyme MAO exists in two catalytically 
distinguishable forms called MAO-A and MAO-B. MAO-A 
prefers serotonin and norepinephrine as substrates and is se-
lectively inhibited by moclobemide (4,5,32). MAO-B preferen-
tially deaminates phenylethylamine and benzylamine and is 
selectively inhibited by Ro 19-6327 (14). Therefore, the differ-
ent effects of moclobemide and Ro 19-6327 on circadian 
rhythms are consistent with the pharmacological profiles of 
these drugs. In the case of clomipramine, fluoxetine, and levo-
protiline, it cannot be excluded that the negative results were 
due to an ineffective dosage of these substances. However, 
previous studies have demonstrated pharmacological effects 
successfully with the same dosages used m the present study. 
Repeated administration of 10 mg/ kg clomipramine induces a 
900fo inhibition of serotonm reuptake in the rat brain with 
only small effects on norepinephrine and dopamine reuptake 
(49). At doses of 5 and 10 mg/kg, fluoxetine, too, very selec-
tively inhibits serotonin reuptake in the rat brain and increases 
extracellular serotonin concentrations 3- and 13-fold, respec-
tively (11 ,49). The negative results of the levoprotiline treat-
ment are difficult to interpret because the pharmacological 
mechanisms of levoprotiline are still unknown. A major prob-
lem is that antidepressant-like effects have been demonstrated 
for the (- )-enantiomer of oxaprotiline, that is, levoprotiline, 
at doses between I and 30 mg/ kg, while pharmacological ac-
tivities, such as selective inhibition of norepinephrine reup-
take, have been found to reside in the ( + )-enantiomer (6,21). 
Because the doses used in the present study are known to be 
pharmacologically effective, the negative results of Ro 19-6327, 
clomipramine, fluoxetine, and levoprotiline suggest that the 
different types of antidepressant drugs have a more selective 
effect on the circadian timing system than previously assumed. 
The results of this study do not support the so-called phase-
advance hypothesis of depression. According to this hypothe-
sis, disturbances of circadian rhythms in depressive patients 
are mterpreted as phase advanced with respect to the environ-
mental day-night cycle (27,39,41-43), and the clinical efficacy 
of the most widely used antidepressant drugs are due to their 
ability to lengthen the free-running period as well as delay the 
entrainment phase of circadian rhythms. However, of the six 
antidepressants tested in the present study only two, moclobe-
mide and desipramine, induced significant changes in the free-
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running period. In addition, the period was shortened rather 
than lengthened and, what seems even more important, the 
eff~t was not reversed after termination of drug treatment. 
The discrepancy between these results and previous find-
ings needs further investigation. To date, most of the work 
on the effects of antidepressants on circadian rhythms in ani-
mals has focused on lithium, clorgyline, or imipramine, but 
the results are rather inconsistent (8). Some studies found that 
lithium lengthens the free-running period of circadian rhythms 
in various species, whereas others did not [for summaries, see 
(8,43,44)). Similarly inconsistent results have been reported 
for imipramine, an unspecific monoamine reuptake inhibitor. 
In rats, imipramine delays the phase position of many brain 
receptor rhythms (43) and restores abnormally phase-
advanced endocrine rhythms of isolation-stressed rats to the 
normal phases found in controls (13). On the other hand, 
imipramine did not affect the phase position or rate of reen-
trainment of circadian activity rhythms in hamsters (2), and 
no significant effects on the period length could be observed 
in rats (36) or hamsters (45). In the case of clorgyline, an 
irreversible type A MAO inhibitor, a lengthening and phase 
delay of circadian activity rhythms have been demonstrated 
only in hamsters (7 ,37 ,45), while no clear effect on the period 
length was found in rats (29). One explanation for this species 
difference may be that the hamster brain contains more than 
950Jo MAO type A (10), whereas the rat brain contains only 
about 60-80% MAO type A (10,32). It has also been suggested 
that timing and mode of administration may be critical to the 
efficacy of a drug to alter the circadian period (8). For exam-
ple, continuous infusion of lithium seems to be less effective 
than intermittent application via food or drinking water (8). 
Another open issue is the primary site of action of these 
drugs. Do they act on the circadian pacemaker itself or merely 
through changes in the general physiological status of the ani-
mals? So far, alterations of the free-running period have 
mostly been ascribed to a direct effect on the circadian pace-
maker. However, in light of recent observations that behav-
ioral arousal may produce feedback effects on the circadian 
pacemaker of hamsters (24,38) changes in the free-running 
period may also be induced by alterations of the activity level. 
In the present study, moclobemide and desipramine induced 
an increase in the overall level of activity and a shortening of 
the free-running period. Estrogen, too, has been found to 
increase the activity level and shorten the free-running period 
in hamsters (23) and rats (1). Clorgyline, on the other hand, 
decreased the level of activity and lengthened the free-running 
period in hamsters (7 ,45). Free-running periods can be af-
fected even without any drug treatment merely by the method 
of the activity r~ording. For instance, access to a running 
wheel bas been shown to increase the level of activity and 
shorten the free-running period in rats (50). A negative corre-
lation between the number of wheel revolutions and the free-
running period has also been observed in mice (9). All these 
findings suggest that pharmacological agents may affect the 
circadian clock indirectly through an increase or decrease of 
the activity level. Unfortunately, even today only few investi-
gations of pharmacological effects on circadian rhythms make 
use of computerized recording equipment that would allow a 
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thorough evaluation of the relationship between alterations in 
activity levels and the free-running period (9). 
The most important finding of the present study appears 
to be the restoration of a unimodal activity pattern in LEW 
rats by moclobemide and desipramine. Previous investigations 
of LEW rats suggest that the unusual activity pattern of this 
strain is caused by a distinct coupling of multiple circadian 
oscillators (34,46,47). However, the neurophysiological or 
neurochemical mechanisms underlying the unusual activity 
pattern of the LEW strain are still unknown. Considering that 
both moclobemide and desipramine altered the abnormal 
multimodal activity pattern of LEW rats into a unimodal pat-
tern like that seen in other laboratory rats, it is conceivable 
that at least some of the abnormal features of activity rhythms 
in this strain are caused by modifications of the noradrenergic 
system. In rats, moclobemide, a reversible and highly selective 
MAO type A inhibitor, increases serotonin ( + 30%) as well 
as norepinephrine ( + 25%) and dopamine levels ( + 5 OJo) and 
dramatically reduces all monoamine metabolites ( - 80%) 
(4,5). Desipramine inhibits the reuptake of norepinephrine as 
well as of serotonin at the presynaptic terminals, but the inhi-
bition of norepinephrine is 1,000 times more effective than 
for serotonin (17,21). Moclobemide and desipramine both act 
in a similar neurochemical way, enhancing noradrenergic 
transmission. The critical synapses mediating these effects 
may be located within or in the vicinity of the hypothalamic 
suprachiasmatic nucleus (SCN), the locus of an identified cir-
cadian pacemaker in the vertebrate nervous system (22,31). 
Noradrenergic fibers have been found to build a "capsule" of 
innervation around the SCN (40), and at least some SCN neu-
rons are electrically responsive to iontophoreticaUy applied 
norepinephrine (33). Further investigations should, therefore, 
be undertaken to identify the anatomic loci and cellular mech-
anisms of the effects described in this study. 
ln conclusion, the present study found that some antide-
pressives affect parameters of circadian rhythmicity. How-
ever, it could not demonstrate a common effect on all classes 
of antidepressives. Nevertheless, these substances certainly 
provide a powerful tool for investigating the neural mecha-
nisms underlying circadian rhythms. The effects of moclobe-
mide and desipramine indicate that level and period of circa-
dian activity rhythms are influenced by the noradrenergic 
system. Furthermore, the changes these drugs cause in the 
multimodal activity pattern of LEW rats suggest that the ef-
fects of antidepressant agents depend upon the genetic back-
ground of animals. 
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